123 related articles for article (PubMed ID: 27178216)
1. Conformational properties of the third variable loop of HIV-1AD8 envelope glycoprotein in the liganded conditions.
Takeda S; Takizawa M; Miyauchi K; Urano E; Fujino M; Murakami T; Murakami T; Komano J
Biochem Biophys Res Commun; 2016 Jun; 475(1):113-8. PubMed ID: 27178216
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound.
Anang S; Richard J; Bourassa C; Goyette G; Chiu TJ; Chen HC; Smith AB; Madani N; Finzi A; Sodroski J
J Virol; 2022 Sep; 96(17):e0063622. PubMed ID: 35980207
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope.
Takizawa M; Miyauchi K; Urano E; Kusagawa S; Kitamura K; Naganawa S; Murakami T; Honda M; Yamamoto N; Komano J
AIDS; 2011 Nov; 25(18):2209-16. PubMed ID: 21866041
[TBL] [Abstract][Full Text] [Related]
4. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
5. Structure of Simian Immunodeficiency Virus Envelope Spikes Bound with CD4 and Monoclonal Antibody 36D5.
Hu G; Liu J; Roux KH; Taylor KA
J Virol; 2017 Aug; 91(16):. PubMed ID: 28539445
[TBL] [Abstract][Full Text] [Related]
6. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
7. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
8. Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env.
Schapiro HM; Khasnis MD; Ahn K; Karagiaridi A; Hayden S; Cilento ME; Root MJ
PLoS Pathog; 2022 May; 18(5):e1010531. PubMed ID: 35584191
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
10. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
11. Increased HIV-1 sensitivity to neutralizing antibodies by mutations in the Env V3-coding region for resistance to CXCR4 antagonists.
Hikichi Y; Yokoyama M; Takemura T; Fujino M; Kumakura S; Maeda Y; Yamamoto N; Sato H; Matano T; Murakami T
J Gen Virol; 2016 Sep; 97(9):2427-2440. PubMed ID: 27368421
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.
Bouvin-Pley M; Beretta M; Moreau A; Roch E; Essat A; Goujard C; Chaix ML; Moiré N; Martin L; Meyer L; Barin F; Braibant M
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567994
[TBL] [Abstract][Full Text] [Related]
13. Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops.
Moscoso CG; Xing L; Hui J; Hu J; Kalkhoran MB; Yenigun OM; Sun Y; Paavolainen L; Martin L; Vahlne A; Zambonelli C; Barnett SW; Srivastava IK; Cheng RH
Sci Rep; 2014 Nov; 4():7025. PubMed ID: 25395053
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120.
Hoorelbeke B; van Montfort T; Xue J; LiWang PJ; Tanaka H; Igarashi Y; Van Damme EJ; Sanders RW; Balzarini J
FEBS Lett; 2013 Apr; 587(7):860-6. PubMed ID: 23454641
[TBL] [Abstract][Full Text] [Related]
15. Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120.
Chandramouli B; Chillemi G; Giombini E; Capobianchi MR; Rozera G; Desideri A
J Biomol Struct Dyn; 2013 Apr; 31(4):403-13. PubMed ID: 22876913
[TBL] [Abstract][Full Text] [Related]
16. Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.
Agrawal-Gamse C; Lee FH; Haggarty B; Jordan AP; Yi Y; Lee B; Collman RG; Hoxie JA; Doms RW; Laakso MM
J Virol; 2009 Nov; 83(21):11005-15. PubMed ID: 19692476
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic studies on recombinant human immunodeficiency virus type 1 (HIV-1) containing CRF01_AE env gene derived from HIV-1-infected patient, residing in central Thailand.
Utachee P; Jinnopat P; Isarangkura-Na-Ayuthaya P; de Silva UC; Nakamura S; Siripanyaphinyo U; Wichukchinda N; Tokunaga K; Yasunaga T; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
Microbes Infect; 2009 Mar; 11(3):334-43. PubMed ID: 19136072
[TBL] [Abstract][Full Text] [Related]
18. Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer.
Mao Y; Wang L; Gu C; Herschhorn A; Xiang SH; Haim H; Yang X; Sodroski J
Nat Struct Mol Biol; 2012 Sep; 19(9):893-9. PubMed ID: 22864288
[TBL] [Abstract][Full Text] [Related]
19. A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.
Li L; Wang XH; Williams C; Volsky B; Steczko O; Seaman MS; Luthra K; Nyambi P; Nadas A; Giudicelli V; Lefranc MP; Zolla-Pazner S; Gorny MK
Mol Immunol; 2015 Aug; 66(2):364-74. PubMed ID: 25965315
[TBL] [Abstract][Full Text] [Related]
20. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.
Dimonte S; Babakir-Mina M; Mercurio F; Di Pinto D; Ceccherini-Silberstein F; Svicher V; Perno CF
Virus Res; 2012 Sep; 168(1-2):73-83. PubMed ID: 22732432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
